An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection and Skeletal Joint Imaging With SPECT in Subjects With Active Rheumatoid Arthritis (RA) and Healthy Controls
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Tc 99m tilmanocept (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Navidea Biopharmaceuticals
- 08 Aug 2017 Navidea plans to complete enrollment in the study in the fourth quarter of 2017, according to a company media release.
- 13 Jan 2017 Status changed from not yet recruiting to recruiting.
- 17 Aug 2016 New trial record